openPR Logo
Press release

Investigation for Investors in NASDAQ: AYTU shares over possible Wrongdoing at Aytu BioScience, Inc.

04-22-2020 09:59 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation on behalf of investors in Aytu BioScience, Inc. (NASDAQ: AYTU) shares over potential wrongdoing.

An investigation on behalf of investors in Aytu BioScience, Inc. (NASDAQ: AYTU) shares over potential wrongdoing.

An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Aytu BioScience, Inc.

Investors who purchased shares of Aytu BioScience, Inc. (NASDAQ: AYTU) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain Aytu BioScience directors breached their fiduciary duties and caused damage to the company and its shareholders.

Englewood, CO based Aytu BioScience, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), cough and upper respiratory symptoms, insomnia, and male infertility in the United States and internationally. Aytu BioScience, Inc. reported that its Total Revenue rose from $3.22 million for the 12 months period that ended on June 30, 2017 to $3.66 million for the 12 months period that ended on June 30, 2018 and that its Net Loss declined from $22.5 million to $10.18 million over those respective time periods.

On March 10, 2020, Aytu BioScience, Inc reported that it reached a license agreement for the exclusive distribution of a point-of-care rapid test for certain COVID-19 antibodies in the U.S. for three years, with three year auto-renewals thereafter.

Then, on April 17, 2020, pre-market, a report was issued entitled "Unapproved Chinese coronavirus antibody tests being used in at least 2 states." Citing health officials and U.S. Food and Drug Administration ("FDA") filings, the article reported that Aytu BioScience, Inc has been distributing unreliable COVID-19 tests from unapproved Chinese manufacturers, which were shipped to the U.S. after the FDA relaxed its guidelines for tests in mid-March.
On this news, Aytu BioScience, Inc's stock price fell $0.12 per share, or 8%, to close at $1.38 per share on April 17, 2020.

Those who purchased shares of Aytu BioScience, Inc. (NASDAQ: AYTU) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation for Investors in NASDAQ: AYTU shares over possible Wrongdoing at Aytu BioScience, Inc. here

News-ID: 2021228 • Views: 703

More Releases from Shareholders Foundation

ProShares Ultra Bloomberg Crude Oil (NYSEArca: UCO) Investor Alert: Deadline in …
A deadline is coming up on September 28, 2020 in the lawsuit filed for certain investors of ProShares Ultra Bloomberg Crude Oil (NYSEArca: UCO) over alleged securities laws violations. Investors who purchased shares of ProShares Ultra Bloomberg Crude Oil (NYSEArca: UCO) have certain options and there are strict and short deadlines running. Deadline: September 28, 2020. NYSEArca: UCO stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -
Investigation announced for Long-Term Investors in shares of Forescout Technolog …
An investigation was announced for long-term investors in shares of Forescout Technologies, Inc. (NASDAQ: FSCT) concerning potential breaches of fiduciary duties by certain directors and officers of Forescout Technologies, Inc.. Investors who are current long term investors in Forescout Technologies, Inc. (NASDAQ: FSCT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for investors in NASDAQ:
Investigation announced for Long-Term Investors in shares of Hebron Technology C …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors of Hebron Technology Co., Ltd.. Investors who are current long term investors in Hebron Technology Co., Ltd. (NASDAQ: HEBT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: HEBT stocks follows a lawsuit filed against Hebron
Investigation announced for Investors in shares of CrossFirst Bankshares, Inc. ( …
An investigation was announced concerning potential securities laws violations by CrossFirst Bankshares, Inc. in connection with certain financial statements. Investors who purchased shares of CrossFirst Bankshares, Inc. (NASDAQ: CFB), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether certain statements by CrossFirst Bankshares, Inc. regarding its business, its prospects and its operations were materially false

All 5 Releases


More Releases for Aytu

Cough Suppressant Drugs Market Growth Analysis, Competitor Landscape with Top Pl …
n March 2018, Perrigo Company plc. received the FDA approval for the brand OTC equivalent of Mucinex DM Maximum Strength (Guaifenesin and Dextromethorphan Hydrobromide Extended-release Tablets, 1200 mg/60 mg). Mucinex DM Maximum Strength is indicated to control coughs and to break up mucus, making coughs more productive. Approval and launch of such new drugs in the market is expected to drive the cough suppressant drugs market growth over the forecast
Cough Suppressant Drugs Market Development Industry 2019 Featuring with Top Play …
In March 2018, Perrigo Company plc. received the FDA approval for the brand OTC equivalent of Mucinex DM Maximum Strength (Guaifenesin and Dextromethorphan Hydrobromide Extended-release Tablets, 1200 mg/60 mg). Mucinex DM Maximum Strength is indicated to control coughs and to break up mucus, making coughs more productive. Approval and launch of such new drugs in the market is expected to drive the cough suppressant drugs market growth over the forecast
Cough Suppressant Drugs Market Latest Trends By Market Analysis with Top Players …
A cough is a very common symptom of various upper and lower respiratory tract infections. It is a reflex response to mechanical, chemical, or inflammatory irritation of the tracheobronchial tree, which is conveyed by sensory neurons in the airways reflexly through neurons present in the brainstem. Antitussives, also known as cough suppressants, are widely used to relieve the symptoms of cough. Cough suppressant works by reducing the activity of cough
Trending Report : Male Hypogonadism Market Is Estimated To Reach $3,350 Million …
Male hypogonadism is a condition in which the body does not produce enough testosterone - a hormone that plays a key role in male growth and development during puberty - or has poor sperm production capacity or both .Male Hypogonadism Market Is Estimated To Reach $3,233 Million From $2,594 Million And Is Supported By a CAGR Of 3% During The Forecast Period Get Sample @ https://www.researchreportsinc.com/sample-request?id=31794 List of Key Players
Cough Suppressant Drugs Market Upcoming Opportunities, Growth, Scope Analysis by …
Cough suppressant drugs are used to suppress the cough. Cough is usually doesn't require any treatment as it goes away in few days. However cough medicines are required if it persists for more than a week and if it starts disturbing routine activities. Also, some types of cough help in clearing patients lungs and hence should not be treated with cough suppressant drugs. Hence consultation with the doctor before consumption
Male Infertility Treatment Market Covering Prime Factors and Competitive Outlook …
The demand for Male Infertility Treatment Market is anticipated to be high for the next few years. By considering this demand we provide latest Male Infertility Treatment Market Report which gives complete industry analysis, market outlook, size, growth and forecast till 2023. This report will assist in analyzing the current and future business trends, sales and revenue forecasts. Global Male Infertility Treatment Market Overview: This report studies the Global Male Infertility Treatment